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Summary
Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of 
a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness.
Methods In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 
18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the 
USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were 
added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer 
diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days 
of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using 
logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with 
ClinicalTrials.gov, NCT04354701, and is ongoing.
Findings Of 1035 records entered into the CCC19 database during the study period, 928 patients met inclusion criteria 
for our analysis. Median age was 66 years (IQR 57–76), 279 (30%) were aged 75 years or older, and 468 (50%) patients 
were male. The most prevalent malignancies were breast (191 [21%]) and prostate (152 [16%]). 366 (39%) patients were 
on active anticancer treatment, and 396 (43%) had active (measurable) cancer. At analysis (May 7, 2020), 
121 (13%) patients had died. In logistic regression analysis, independent factors associated with increased 30-day 
mortality, after partial adjustment, were: increased age (per 10 years; partially adjusted odds ratio 1·84, 95% CI 
1·53–2·21), male sex (1·63, 1·07–2·48), smoking status (former smoker vs never smoked: 1·60, 1·03–2·47), number 
of comorbidities (two vs none: 4·50, 1·33–15·28), Eastern Cooperative Oncology Group performance status of 2 or 
higher (status of 2 vs 0 or 1: 3·89, 2·11–7·18), active cancer (progressing vs remission: 5·20, 2·77–9·77), and receipt 
of azithromycin plus hydroxychloroquine (vs treatment with neither: 2·93, 1·79–4·79; confounding by indication 
cannot be excluded). Compared with residence in the US-Northeast, residence in Canada (0·24, 0·07–0·84) or the 
US-Midwest (0·50, 0·28–0·90) were associated with decreased 30-day all-cause mortality. Race and ethnicity, obesity 
status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.
Interpretation Among patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with 
general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand 
the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer 
treatments.
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Introduction
Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) and the resulting illness, COVID-19, have 
emerged as a global pandemic.1 Initial reports suggested 
that patients with a history of or active malignancy 
might be at increased risk of contracting the virus and 
developing COVID-19-related complications.2–4 Yet, initial 
reports are restricted by sample size, geographical 
region, and a lack of generalisability of findings to the 
overall population of patients with cancer.
Patients with cancer might be immunocompromised 
by the effects of antineoplastic therapy, supportive 
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medications such as steroids, and the immunosuppressive 
properties of cancer itself; they might also have an 
augmented immune response to infection secondary to 
immunomodulatory drugs, such as programmed cell 
death 1 or programmed cell death ligand 1 inhibitors.5 
Additionally, patients with cancer are often older (ie, aged 
≥60 years) with one or more major comorbidities, putting 
them at increased risk for COVID-19-related morbidity 
and mortality.6 Furthermore, they often have high levels 
of contact with the health-care system through provider 
visits for anticancer therapy, monitoring, and preventive 
and supportive care.
Given the worldwide prevalence of cancer and the high 
transmissibility of SARS-CoV-2, an understanding of the 
disease course of COVID-19 and factors influencing 
clinical outcomes in patients with cancer is urgently 
needed. In this cohort study, we hypothesised that 
demographic, clinical, underlying cancer, and COVID-19 
treatment-related variables are associated with 30-day all-
cause mortality in this population.
Methods
Study design and participants
In this cohort study, we report data from the COVID-19 
and Cancer Consortium (CCC19) registry database. The 
CCC19 was formed on March 15, 2020, to study the 
clinical characteristics and course of illness among 
patients with COVID-19 who have a current or past 
diagnosis of cancer; accrual to the registry started on 
March 17, 2020.7 The registry is built and maintained as 
an electronic REDCap database housed at Vanderbilt 
University Medical Center (VUMC).8
The CCC19 registry is accruing de-identified data on 
adult patients (aged 18 years or older) with a current or 
past history of haematological malignancy or invasive 
solid tumour who have either a laboratory-confirmed 
SARS-CoV-2 infection or a presumptive diagnosis of 
COVID-19. Contributing institutions in the consortium 
(appendix pp 2–5) independently identify consecutive 
patients and report data through the online REDCap data 
collection survey instruments developed by CCC19 
(appendix pp 14–18). Participating institutions were 
restricted to the USA and Canada. Participation by 
anonymous individual health-care practitioners located in 
Argentina, Canada, the EU, the UK, and the USA is also 
allowed. The mechanism of data collection can be 
retrospective (after the course of COVID-19) or con-
current, at the discretion of the respondent. Collection of 
follow-up data is strongly encouraged.
For this initial analysis, we collected data for patients 
who had baseline data entered onto the database between 
March 17 and April 16, 2020, and had follow-up data 
entered up until May 7, 2020. Patients eligible for 
inclusion were adults (aged 18 years or older), with a 
diagnosed invasive or haematological malignancy at any 
time, and a resident of the USA, Canada, or Spain. Due to 
possible confounding by other infections, patients with 
presumptive COVID-19 who did not have a laboratory-
confirmed SARS-CoV-2 infection were excluded. Patients 
with non-invasive cancers including non-melanomatous 
skin cancer, in-situ carcinoma, or precursor haematological 
neoplasms were excluded from this analysis.
This study was considered exempt from institutional 
review board (IRB) review (VUMC IRB 200467) and 
was approved by local IRBs at participating sites per 
institutional policy, according to the principles of the 
Declaration of Helsinki. This study is registered on 
ClinicalTrials.gov, NCT04354701, and is ongoing.
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Research in context
Evidence before this study
Very little evidence exists describing the natural history of 
patients with cancer who have COVID-19, the disease 
associated with severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). As of May 7, 2020, the peer-
reviewed literature was limited to small or single-institution 
case series; the largest series that we are aware of had 334 cases 
at a single institution. These case series are of insufficient size or 
breadth to draw statistical and generalisable conclusions about 
the factors that might be associated with better or worse 
outcomes for patients with cancer.
Added value of this study
To our knowledge, we report the largest series of patients with 
cancer and COVID-19 to date, including over 900 patients with 
a broad geographical distribution. The population is diverse in 
terms of age distribution, race and ethnicity, cancer status, and 
whether they are on active anticancer treatment. We found 
significant associations with increased 30-day all-cause 
mortality and the general factors of increasing age, male sex, 
former smoking, number of comorbidities, and receipt of 
azithromycin plus hydroxychloroquine; and the cancer-specific 
factors of moderate or poor Eastern Cooperative Oncology 
Group performance status and active (measurable) cancer. 
However, we cannot formally ascertain if the combination of 
hydroxychloroquine and azithromycin gives any clinical benefit 
or overall harm to patients, given the non-randomised nature 
of the study, and the possibility of other potential clinical 
imbalances. 
Implications of all the available evidence
We identified several cancer-specific factors that are associated 
with increased 30-day all-cause mortality in patients with 
cancer and COVID-19, in addition to previously reported factors 
of age and sex in the general population. These findings have 
implications for patients and health-care providers who will be 
confronted with difficult decisions during the SARS-CoV-2 
pandemic, such as whether to withhold or continue anticancer 
treatments, and whether to accelerate end-of-life planning 
under some circumstances.
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Procedures
The CCC19 survey collects de-identified data across 
approximately 300 structured and free-text variables in 
five forms: patient demographics, COVID-19 initial course 
of illness, cancer details, respondent details (ie, health-
care provider details), and follow-up. Potential prognostic 
variables were included: age, sex, race and ethnicity, 
geographical location of patient residence, smoking 
status, obesity, number of comorbidities requiring active 
treatment, recent surgery (including, but not limited to 
cancer surgeries, within 4 weeks of COVID-19 diagnosis), 
type of malignancy, cancer status (remission vs active 
[measurable] disease, with active further defined as stable 
or responding to treatment vs progressing), Eastern 
Cooperative Oncology Group (ECOG) performance status, 
anticancer therapy, and COVID-19 treatment with azithro-
mycin, hydroxy chloroquine, or both in combination. 
Active anticancer therapy was defined as either cytotoxic 
chemotherapy or all other therapies except surgery 
(targeted drugs, endocrine ther apy, immunotherapy, 
radiot herapy) given within 4 weeks of COVID-19 diagnosis 
(appendix pp 14–18).
Outcomes
The primary endpoint was all-cause mortality within 
30 days of diagnosis of COVID-19. Secondary outcomes 
were: a composite of severe illness (death, severe illness 
requiring admission to hospital, admission to an 
intensive care unit [ICU], mechanical ventilation, or a 
combination of these); admission to hospital; admis-
sion to an ICU; mechanical ventilation; and need for 
supplemental oxygen during the course of COVID-19. 
Statistical analysis
A predefined statistical analysis plan was finalised before 
accrual lock (April 16, 2020) and was revised once before 
data analysis (April 18, 2020; appendix pp 6–8). Because 
of the possibility of a small number of events (deaths), 
we prespecified the potential prognostic variables for the 
primary outcome using clinical knowledge and allowable 
complexity of the model (ie, the number of covariates 
and degrees of freedom) on the basis of an effective 
sample size. We provided an unknown category for every 
variable in the survey. Because some of the survey 
questions were optional, we anticipated a non-zero level 
of missingness for some variables (ie, the answer box for 
the question could be left blank). We used multiple 
imputation using additive regression, bootstrapping, 
and predictive mean matching with ten iterations for 
variables with a 10% or lower missingness rate; variables 
with a missingness rate of more than 10% were not 
included in our analyses.
We used descriptive statistics to show the baseline 
demographic information of the participants included in 
our analyses.
Due to privacy restrictions, we collected dates of 
COVID-19 diagnosis as intervals (eg, diagnosed 2–4 weeks 
ago). As a result, we planned an interval-censored Cox 
proportional hazards analysis; however, wide diagnosis 
intervals and insufficient primary outcome events 
restricted our ability to do this analysis. Therefore, we 
examined the correlations between the study variables 
and primary endpoint using a logistic regression model 
for bivariable and predetermined multivariable data 
analysis. In the multivariable model we partially adjusted 
the odds ratios: age was adjusted for sex, smoking 
status, and obesity; sex was adjusted for age, smoking 
status, and obesity; smoking status was adjusted for age, 
sex, and obesity; obesity was adjusted for age, sex, and 
smoking status; and the other covariates were adjusted 
for age, sex, smoking status, and obesity. Age was treated 
as a continuous variable with age 90 years and older 
transformed into 90 years for modelling. We did not 
adjust our results for multiple com parisons. We assessed 
goodness of fit using Harrell’s C-statistic with 95% CIs 
determined using DeLong and colleagues’ method.9,10 We 
calculated variance inflation factors for every potential 
prognostic variable in each adjusted model.
In an exploratory subanalysis, we also applied an elastic 
net regularised logistic regression analysis to examine 
the shrinkage of the coefficients in the predetermined set 
of covariates.11 Given the high rate of clinically important 
secondary outcomes, we did a post-hoc, fully adjusted, 
logistic regression analysis of the secondary composite 
endpoint of severe illness. We also did post-hoc power 
analyses for the recent surgery and anticancer treatment 
variables to examine the study effect sizes.
We did all data analyses using base R (version 3.6.3) 
and the R packages rms 5.1-4 and Hmisc 4.4-0.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publi cation.
Results
Of the 1035 records with completed baseline forms added 
to the database during our study period, 928 patients met 
criteria for inclusion in the analyses (appendix p 10). Of 
these records, 73 (8%) reports originated from community 
practices and 851 (92%) from academic medical centres. 
826 (89%) reports were from participating institutions 
and the remaining 102 (11%) were anonymous. Median 
follow-up for the cohort was 21 days (IQR 11–41 days). 
570 (61%) records were initialised during the course of 
COVID-19; of these, 255 (45%) had at least one follow-up 
report.
Demographic, clinical, and tumour characteristics for 
the analysable population are in table 1 (data for 84 non-
laboratory-confirmed cases are in the appendix [pp 22–23]). 
Median patient age was 66 years (IQR 57–76), 279 (30%) 
were aged 75 years or older, and 468 (50%) patients were 
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male. 460 (50%) patients were non-Hispanic white, 
148 (16%) were non-Hispanic black, and 150 (16%) were 
Hispanic. The most common geographical region of 
residence was the US-Northeast (375 [40%]). The most 
prevalent malignancies were breast (191 [21%]) and pros-
tate (152 [16%]). 422 (45%) patients were reported to be in 












Not specified 1 (<1%)
Race and ethnicity† 
Non-Hispanic white 460 (50%)
Non-Hispanic black 148 (16%)
Hispanic 150 (16%)
Other or unknown 128 (14%)
Data missing 42 (5%)








Never smoked 469 (51%)
Former smoker 326 (35%)
Current smoker 43 (5%)
Unknown 57 (6%)
Data missing 33 (4%)
Obesity status†
Not specified 720 (78%)
Obese 172 (19%)








Data missing 31 (3%)
Type of malignancy§






Renal cell carcinoma 45 (5%)
Endocrine 39 (4%)
Melanoma 38 (4%)
(Table 1 continues in next column)
Analysable population 
(n=928)
(Continued from previous column)
Head and neck 30 (3%)
Sarcoma 24 (3%)
Nervous system 12 (1%)
Solid tumour, not otherwise specified 43 (5%)
Haematological malignancies 204 (22%)
Lymphoid neoplasms 102 (11%)
Low-grade non-Hodgkin lymphoma 54 (6%)
High-grade non-Hodgkin lymphoma 27 (3%)
Acute lymphoblastic leukaemia 6 (1%)
Multiple myeloma 55 (6%)
Myeloid neoplasms 42 (5%)
Acute myeloid leukaemia 13 (1%)




Remission or no evidence of disease 422 (45%)
Present, stable, or responding to 
treatment
294 (32%)
Present, progressive disease 102 (11%)
Unknown 59 (6%)
Data missing 51 (5%)
ECOG performance status†
0 or 1 614 (66%)
2 72 (8%)
3 or 4 46 (5%)
Unknown 167 (18%)
Data missing 29 (3%)
Type of anticancer therapy§
None in the 4 weeks before COVID-19 
diagnosis
553 (60%)
Non-cytotoxic therapy 206 (22%)





Cytotoxic systemic therapy 160 (17%)
Unknown 9 (1%)
Recent surgery†





Data missing 43 (5%)
(Table 1 continues on next page)
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Total (n=928) 121 (13%) 242 (26%) 132 (14%) 116 (12%)
Age, years
<65 (n=412) 25 (6%) 68 (17%) 44 (11%) 38 (9%)
65–74 (n=237) 26 (11%) 60 (25%) 38 (16%) 34 (14%)
≥75 (n=279) 70 (25%) 114 (41%) 50 (18%) 44 (16%)
Sex*
Female (n=459) 43 (9%) 101 (22%) 52 (11%) 45 (10%)
Male (n=468) 78 (17%) 141 (30%) 80 (17%) 71 (15%)
Race and ethnicity 
Non-Hispanic white (n=460) 71 (15%) 126 (27%) 60 (13%) 53 (12%)
Non-Hispanic black (n=148) 20 (14%) 42 (28%) 28 (19%) 25 (17%)
Hispanic (n=150) 16 (11%) 32 (21%) 18 (12%) 16 (11%)
Other or unknown (n=128) 12 (9%) 37 (29%) 24 (19%) 21 (16%)
Data missing (n=42) 2 (5%) 5 (12%) 2 (5%) 1 (2%)
Region of patient residence†
US-Northeast (n=375) 55 (15%) 107 (29%) 56 (15%) 54 (14%)
US-Midwest (n=203) 19 (9%) 55 (27%) 38 (19%) 32 (16%)
US-South (n=117) 15 (13%) 30 (26%) 19 (16%) 17 (15%)
US-West (n=116) 19 (16%) 27 (23%) 14 (12%) 9 (8%)
Canada (n=49) 3 (6%) 11 (22%) 5 (10%) 4 (8%)
Spain (n=68) 10 (15%) 12 (18%) 0 0 
Smoking status
Never smoked (n=469) 44 (9%) 99 (21%) 54 (12%) 48 (10%)
Former smoker (n=326) 64 (20%) 116 (36%) 64 (20%) 55 (17%)
Current smoker (n=43) 5 (12%) 8 (19%) 4 (9%) 4 (9%)
Unknown (n=57) 6 (11%) 15 (26%) 9 (16%) 8 (14%)
Data missing (n=33) 2 (6%) 4 (12%) 1 (3%) 1 (3%)
Obesity status
Not specified (n=720) 98 (14%) 190 (26%) 95 (13%) 83 (12%)
Obese (n=172) 20 (12%) 49 (28%) 36 (21%) 32 (19%)
Data missing (n=36) 3 (8%) 3 (8%) 1 (3%) 1 (3%)
Number of comorbidities
0 (n=132) 3 (2%) 12 (9%) 6 (5%) 4 (3%)
1 (n=202) 13 (6%) 31 (15%) 18 (9%) 13 (6%)
2 (n=231) 41 (18%) 79 (34%) 42 (18%) 39 (17%)
3 (n=117) 24 (21%) 37 (32%) 20 (17%) 18 (15%)
≥4 (n=192) 31 (16%) 71 (37%) 41 (21%) 35 (18%)
Unknown (n=23) 5 (22%) 8 (35%) 4 (17%) 5 (22%)
Data missing (n=31) 4 (13%) 4 (13%) 1 (3%) 2 (6%)
Type of malignancy
Solid tumour (n=654) 76 (12%) 151 (23%) 78 (12%) 70 (11%)
Haematological malignancy 
(n=167)
24 (14%) 58 (35%) 37 (22%) 28 (17%)
Multiple cancers‡ (n=107) 21 (20%) 33 (31%) 17 (16%) 18 (17%)
(Table 2 continues on next page)
with active cancer, 294 (74%) had stable or responding 
disease, and 102 (26%) had progressive disease at the time 
of COVID-19 diagnosis. 366 (39%) patients had received 
anticancer therapy within 4 weeks of COVID-19 diagnosis, 
of whom, 160 (44%) were receiving cytotoxic therapy and 
206 (56%) were receiving other anticancer therapies. The 
four most common presenting symptoms of COVID-19 
were fever (590 [64%]), cough (563 [61%]), fatigue or 
malaise (396 [43%]), and dys pnoea (382 [41%]; appendix 
p 11). 40 (4%) patients were reported as asymptomatic. 
89 (10%) patients were given hydroxychloroquine alone, 
93 (10%) were given azithromycin alone, and 181 (20%) 
were given a combination of these drugs. Notably, only 
two (<1%) patients were reported to have been given these 
drugs within the context of a clinical trial.
As of May 7, 2020, 121 (13%) patients had died, all within 
30 days of COVID-19 diagnosis (table 2). None of the 
potential prognostic variables had a missingness rate of 
more than 10% and all were therefore included in the 
multivariable models. Associations between prognostic 
variables and 30-day all-cause mortality are shown in 
table 3. Goodness of fit was similar across the fitted 
models, with an average C-statistic value of 0·75 (95% CI 
0·71–0·80; appendix p 25). None of the variance inflation 
factors except for comorbidity was greater than five 
(appendix p 25), indicating that significant multicol-
linearity was not present in the models, with this 
exception. Multiple clinically relevant prognostic variables 
associated with increased 30-day all-cause mortality were 
identified, after partial adjustment in our multivariable 
model: increasing age, male sex, smoking status (former 
smoker vs never smoked), cancer status (present, 
stable, or responding, and present, progressive disease vs 
remission or no evidence of disease), ECOG performance 
status (2 vs 0 or 1; 3 or 4 vs 0 or 1); and treatment with 
hydroxychloro quine plus azithromycin versus treatment 
with neither (table 3). Two, three, and four or more 
comorbidities requiring treatment were also associated 
with increased mortality, although the 95% CIs were 
Analysable population 
(n=928)
(Continued from previous page)
Treatment of COVID-19†**
Hydroxychloroquine alone 89 (10%)
Azithromycin alone 93 (10%)
Azithromycin plus hydroxychloroquine 181 (20%)
Neither 486 (52%)
Unknown 22 (2%)
Data missing 57 (6%)
Data are n (%), median (IQR), or range. Due to rounding, not all variables might 
add up to 100%. ECOG=Eastern Cooperative Oncology Group. *Age ≥90 years 
transformed into exact age of 90 years for reporting purposes. †These questions 
were optional in the survey, such that a proportion of results are missing. 
‡US regions are census-tract defined. §Proportions might add up to more than 
100% because some patients had more than one malignancy or received more 
than one treatment concurrently. ¶Includes checkpoint inhibitors, allogeneic 
haemopoietic stem-cell transplant, and adaptive cellular therapy. ||Cancer 
surgeries are separated in the table for descriptive purposes but are combined 
with any recent surgery in the prognostic modelling. **Some patients were 
already taking these medications at the time of presentation: hydroxychloroquine 
(n=12 [1%]), azithromycin (n=26 [3%]), or both (n=23 [2%]).
Table 1: Patient demographic, clinical, and tumour characteristics
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very wide due to a small number of events in the 
reference group (no comorbidities). Residence in 
Canada or the US-Midwest was associated with 
decreased mortality compared with residence in the 
US-Northeast. Race and eth nicity, obesity, type of malig-
nancy, type and recency of anticancer therapy, and 
recent surgery were not associated with 30-day all-cause 
mortality in the partially adjusted analysis. A forest plot 
of the potential prognostic variables is shown in 
figure 1. Results of the elastic net regularised logistic 
regression analysis are similar to those of the primary 
analysis; however, the association between present and 
stable or responding disease and mortality was no 
longer significant (appen dix p 26).
242 (26%) patients met the composite severe illness 
endpoint; 132 (14%) patients were admitted to the ICU; 
and 116 (12%) required mechanical ventilation (table 2). 
52 (39%) of 132 patients who were in the ICU at baseline 
had 30-day follow-up data available. During follow-up, 
16 (31%) of 52 died, 13 (25%) were still in the ICU, and 
19 (37%) had recovered. Notably, 71 (59%) of 121 patients 
who died were never admitted to the ICU; a comparison 
between patients who died with and without ICU admis-
sion is in the appendix (p 27). A numerically higher rate 
of death outside the ICU was seen in patients with 
present cancer, with the reverse pattern seen for those in 
remission. Furthermore, we saw a numerically higher 
rate of death outside the ICU for patients receiving 
palliative care, and the reverse pattern for these receiving 
care with a curative intent. 43 (61%) of 70 patients who 
died aged 75 and older died without ICU admission, 
compared with 27 (39%) who died with ICU admission. 
466 (50%) required admission to hospital, of whom 
175 (38%) were actively receiving anticancer therapy. 
Admissions to hospital differed by geographical region, 
from 37 (32%) of 116 patients in the US-West region to 
34 (69%) of 49 patients in Canada. 405 (44%) patients 
required supplemental oxygen (appendix pp 28–29).
The crude mortality for patients who met the secondary 
outcomes was 106 (23%) of 466 for any admission to 
hospital, 110 (27%) of 405 for any supplemental oxygen 
needed, 50 (38%) of 132 for admission to ICU, 50 (43%) of 
116 for requiring mechanical ventilation, and 121 (50%) 
of 242 for the composite secondary endpoint. Incidence 
of secondary outcomes by cancer type, cancer status, and 
anticancer therapy type-defined subgroups are shown in 
figure 2 and in the appendix (p 12). ICU admission rates 
were highest in former smokers and in those with 
obesity, four or more comorbidities, haematological 
malignancies, unknown cancer status, and an ECOG 
performance status of 2. Rates of mechanical ventilation 
were highest in those with unknown comorbidity status 
and in those with recent surgery.
From our post-hoc analysis of the severe illness com-
posite outcome we found that increasing age, other or 
unknown race or ethnicity, number of comorbidities (two 
and four or more), haema tological malignancy, progressing 
cancer or unknown cancer status, ECOG performance 
status of 2 or higher, or treatment with azithromycin, 
hydroxychloroquine, and both in combination were 
associated with an increased rate of the composite outcome 
(appendix pp 13, 30–31). Based on the post-hoc power 
analysis of the recent surgery and anticancer treatment 
variables, the effect sizes are reasonable and clinically 
meaningful (appendix p 9). 







(Continued from previous page)
Cancer status
Remission or no evidence of 
disease (n=422)
39 (9%) 95 (23%) 63 (15%) 55 (13%)
Present, stable, or responding 
to treatment (n=294)
41 (14%) 80 (27%) 40 (14%) 38 (13%)
Present, progressive disease 
(n=102)
25 (25%) 36 (35%) 12 (12%) 11 (11%)
Unknown (n=59) 11 (19%) 23 (39%) 14 (24%) 11 (19%)
Data missing (n=51) 5 (10%) 8 (16%) 3 (6%) 1 (2%)
ECOG performance status
0 or 1 (n=614) 54 (9%) 135 (22%) 81 (13%) 81 (13%)
2 (n=72) 23 (32%) 31 (43%) 16 (22%) 8 (11%)
3 or 4 (n=46) 19 (41%) 22 (48%) 6 (13%) 5 (11%)
Unknown (n=167) 22 (13%) 51 (31%) 28 (17%) 21 (13%)
Data missing (n=29) 3 (10%) 3 (10%) 1 (3%) 1 (3%)
Type of anticancer therapy
None in the 4 weeks before 
COVID-19 diagnosis (n=553)
75 (14%) 156 (28%) 91 (16%) 79 (14%)
Non-cytotoxic therapy 
(n=206)
23 (11%) 50 (24%) 24 (12%) 24 (12%)
Cytotoxic systemic therapy 
(n=160)
22 (14%) 35 (22%) 17 (11%) 12 (8%)
Unknown (n=9) 1 (11%) 1 (11%) 0 1 (11%)
Recent surgery
None in the 4 weeks before 
COVID-19 diagnosis (n=811)
108 (13%) 212 (26%) 118 (15%) 104 (13%)
Yes (n=32) 6 (19%) 12 (38%) 6 (19%) 7 (22%)
Unknown (n=42) 4 (10%) 14 (33%) 6 (14%) 3 (7%)




11 (12%) 32 (36%) 18 (20%) 14 (16%)
Azithromycin alone (n=93) 12 (13%) 26 (28%) 15 (16%) 14 (15%)
Azithromycin plus 
hydroxychloroquine (n=181)
45 (25%) 86 (48%) 53 (29%) 51 (28%)
Neither (n=486) 41 (8%) 80 (16%) 39 (8%) 29 (6%)
Unknown (n=22) 7 (32%) 8 (36%) 2 (9%) 4 (18%)
Data missing (n=57) 5 (9%) 10 (18%) 5 (9%) 4 (7%)
Data are n (%). Due to rounding, not all variables might add up to 100%. The composite endpoint was a combination 
of death, severe illness requiring admission to hospital, admission to an ICU, or mechanical ventilation. ECOG=Eastern 
Cooperative Oncology Group. ICU=intensive care unit. *Data not shown for one patient, with sex not specified. 
†US regions are census-tract defined. ‡Any patient with two or more cancers reported, which could be solid, 
haematological, or both.
Table 2: Primary and secondary outcomes by potential prognostic variables
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Discussion
The CCC19 began as a grassroots effort to fill an unmet 
need generated by the SARS-CoV-2 pandemic. Through 
social media and other communication networks, over 
100 institutions have been mobilised to capture widely 
needed data regarding outcomes of COVID-19 in patients 
with cancer. The initial mission of the consortium is data 
capture to better understand strategies to mitigate risk 
for patients with cancer. This first analysis of the CCC19 
database focuses on important and previously recognised 
cancer and COVID-19 prog nostic factors to provide 
urgently needed information on the scope, clinical 
management, and outcomes of patients with cancer and 
a diagnosis of COVID-19.
Several important hypotheses have emerged from this 
initial analysis. First, patients with cancer appear to be at 
increased risk of mortality and severe illness due to 
SARS-CoV-2 infection, regardless of whether they have 
active cancer, are on anticancer treatment, or both. Most 
members of our cohort had symptoms compatible with 
COVID-19, and the overall rate of complications was 
high. For example, a report on a cohort of similar size 
from China in an unselected patient population reported 
a death rate of 1·4% (vs our observed 13%) and a similar 
composite endpoint with a rate of 6·1% (vs our observed 






Age, per 10 years† 1·88 (1·58–2·24) 1·84 (1·53–2·21)
Sex
Female 1 (ref) 1 (ref)
Male 1·94 (1·30–2·88) 1·63 (1·07–2·48)
Race and ethnicity 
Non-Hispanic white 1 (ref) 1 (ref)
Non-Hispanic black 0·85 (0·50–1·45) 1·11 (0·63–1·97)
Hispanic 0·65 (0·36–1·17) 1·00 (0·54–1·86)
Other or unknown 0·57 (0·30–1·09) 0·55 (0·28–1·08)
Region of patient residence‡
US-Northeast 1 (ref) 1 (ref)
US-Midwest 0·60 (0·35–1·04) 0·50 (0·28–0·90)
US-South 0·86 (0·46–1·58) 1·18 (0·61–2·26)
US-West 1·14 (0·65–2·01) 1·21 (0·66–2·23)
Canada 0·38 (0·11–1·26) 0·24 (0·07–0·84)
Spain 1·00 (0·48–2·08) 1·17 (0·54–2·55)
Smoking status
Never smoked 1 (ref) 1 (ref)
Former smoker 2·35 (1·55–3·55) 1·60 (1·03–2·47)
Current smoker 1·27 (0·47–3·39) 1·34 (0·49–3·67)
Unknown 1·14 (0·46–2·79) 0·89 (0·34–2·27)
Obesity status
Not specified 1 (ref) 1 (ref)
Obese 0·84 (0·50–1·41) 0·99 (0·58–1·71)
Number of comorbidities
0 1 (ref)§ 1 (ref)§
1 3·12 (0·87–11·19) 1·87 (0·51–6·85)
2 9·52 (2·89–31·40) 4·50 (1·33–15·28)
3 11·54 (3·37–39·53) 5·04 (1·42–17·93)
≥4 8·77 (2·62–29·29) 3·55 (1·03–12·30)
Unknown 12·33 (2·71–56·01) 6·77 (1·42–32·33)
Type of malignancy
Solid tumour 1 (ref) 1 (ref)
Haematological malignancy 1·28 (0·78–2·09) 1·40 (0·83–2·37)
Multiple cancers 1·86 (1·09–3·17) 1·34 (0·77–2·34)
Cancer status
Remission or no evidence of 
disease
1 (ref) 1 (ref)
Present, stable, or 
responding to treatment
1·57 (0·98–2·49) 1·79 (1·09–2·95)
Present, progressive disease 3·07 (1·77–5·33) 5·20 (2·77–9·77)
Other or unknown 2·24 (1·06–4·71) 2·71 (1·21–6·09)






(Continued from previous column)
ECOG performance status
0 or 1 1 (ref) 1 (ref)
2 4·84 (2·75–8·52) 3·89 (2·11–7·18)
3 or 4 7·33 (3·83–14·01) 5·66 (2·79–11·47)
Unknown 1·59 (0·93–2·73) 1·43 (0·81–2·50)
Type of anticancer therapy
None in the 4 weeks before 
COVID-19 diagnosis
1 (ref) 1 (ref)
Non-cytotoxic therapy 0·80 (0·49–1·32) 1·04 (0·62–1·76)
Cytotoxic systemic therapy 1·02 (0·61–1·69) 1·47 (0·84–2·56)
Unknown 0·80 (0·10–6·46) 1·60 (0·18–14·14)
Recent surgery¶
None in the 4 weeks before 
COVID-19 diagnosis
1 (ref) 1 (ref)
Yes 1·50 (0·60–3·74) 1·52 (0·58–3·96)
Unknown 0·66 (0·23–1·89) 0·78 (0·26–2·33)
Treatment of COVID-19
Hydroxychloroquine alone 1·43 (0·71–2·90) 1·06 (0·51–2·20)
Azithromycin alone 1·56 (0·79–3·06) 1·30 (0·65–2·64)
Azithromycin plus 
hydroxychloroquine
3·42 (2·14–5·45) 2·93 (1·79–4·79)
Neither 1 (ref) 1 (ref)
Unknown 4·82 (1·84–12·60) 3·97 (1·41–11·19)
Data are odds ratio with 95% CI in parentheses. ECOG=Eastern Cooperative 
Oncology Group. *Age is adjusted for sex, smoking status, and obesity; sex is 
adjusted for age, smoking status, and obesity; smoking status is adjusted for age, 
sex, and obesity; obesity is adjusted for age, sex, and smoking status; and all other 
variables are adjusted for age, sex, smoking status, and obesity. †Age ≥90 years 
transformed into exact age of 90 years for modelling purposes; odds ratios are per 
10-year age increment. ‡US regions are census-tract defined. §Precision of 
estimation for this category is poor due to small number of events in the 
reference group. ¶Includes any surgery, including cancer-specific surgeries, done 
within 4 weeks of COVID-19 diagnosis.
Table 3: Bivariable and multivariable regression models of potential 
prognostic variables associated with 30-day all-cause mortality
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New York City region (NY, USA) have reported specifically 
on outcomes in patients with cancer.4,13 An aggregate-level 
analysis of 334 patients with cancer from the Mount Sinai 
Health System reported an 11% rate of death and 11% rate 
of intubation.13 A series of 218 patients with cancer from 
the Montefiore Health system reported a case fatality 
rate of 28%, although the authors acknowledged a bias 
towards more severe cases.4 Taken together with our 
cohort from multiple institutions, these findings have 
important policy implications including, but not limited 
to, the need for increased surveillance and testing for 
SARS-CoV-2, minimising health-care system exposure, 
and recon sideration of procedures and treatments in 
patients with cancer. Notably, health-care systems are 
screening asymptomatic individuals before many cancer 
treatments, and we anticipate that as the CCC19 cohort 
grows, separate analysis of asymptomatic individuals who 
have been screened will be necessary.
Important subgroups of patients with cancer appear to 
be at increased risk for adverse outcomes. In addition to 
the previously reported risk factors of age and sex in the 
general COVID-19 population,6,14,15 ECOG performance 
status of 2 or higher and active cancer seem to be associated 
with an increased risk of worse outcomes from COVID-19 
in patients with cancer. Although moderate or poor ECOG 
performance status is well known to have a deleterious 
effect on overall outcomes, an ECOG performance status 
of 2 is not always considered a contraindication to 
aggressive therapy for active cancer.16,17 Our study highlights 
the potentially additive negative effect of COVID-19 in this 
susceptible population. Some potential implications of this 
finding include acceleration of advanced care planning 
and patient and family discussions on restricting 
aggressive interventions, such as mechanical ventilation.18 
The American Society of Clinical Oncology has issued 
guid ance on ethical considerations pertaining to resource-
limited situations during the SARS-CoV-2 pandemic.19
Although an ECOG performance status of 2 was 
relatively uncommon in this cohort, the presence of active 
(measurable) cancer was common. From our analysis, 
active cancer might be a risk factor associated with worse 
COVID-19 outcomes, especially in patients who have 
progressive disease. In our cohort, patients with 
progressive cancer died at a numerically higher rate 
without ICU admission than among those who were 
admitted to an ICU, and the reverse pattern was seen for 
patients in remission. This finding, and the numerically 
higher rate of deaths without ICU admission in patients 
aged 75 years and older and those receiving treatment with 
palliative intent, suggests that aggressive interventions 
might have already been reduced in these subpopulations. 
And similarly to patients with moderate or poor ECOG 
performance status, careful conversations about the risks 
and benefits of continuing anticancer therapy will urgently 
be required in these subpopulations. Conversely, the 
absence of an association between 30-day all-cause 
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Partially adjusted odds ratio (95% CI)
Figure 1: Forest plot of factors associated with 30-day all-cause mortality
Data are partially adjusted odds ratios, with 95% CIs. ECOG=Eastern Cooperative Oncology Group. *Adjusted for 
sex, smoking status, and obesity. †Adjusted for age, sex, smoking status, and obesity. ‡Adjusted for age, sex, 
and obesity. §Adjusted for age, sex, and smoking status.
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or recent cytotoxic systemic therapy suggests that curative 
surgical resections, adjuvant chemotherapy, and main-
tenance chemotherapy could continue during the 
SARS-CoV-2 pandemic with extreme caution, although 
this finding should not be interpreted as a recommendation.
Some of the observations reported here potentially have 
a biological basis—eg, smoking in particular has previously 
been implicated in inflammatory lung dis ease and 
SARS-CoV-2 biology.20–23 Former smoking was associated 
with increased mortality in the baseline analysis and in the 
elastic net regression; no conclusions can be drawn about 
current smoking due to the small number of events. 
Human and animal models suggest that the alveolar 
epithelial cells in the lungs of smokers might have 
increased angiotensin-converting enzyme 2 (ACE2) expres-
sion, which might increase mucus-secreting goblet cells.24 
Although the potential systemic dysregulation of ACE2 is 
not yet fully understood, downregulation caused by 
SARS-CoV-2 viral binding to this receptor could lead to 
increased angiotensin II, which can cause acute lung 
injury and other systemic effects.25 SARS-CoV-2 is similar 
to other coronaviruses, including the severe acute 
respiratory syndrome (SARS) CoV that led to the SARS 
outbreak in 2003.26 Cell entry of both of these viruses 
appears to rely on protein binding to ACE receptors on 
host cells, with an additional required proteolytic step to 
allow fusion of the viral and cellular membranes. This 
proteolytic step is dependent on transmembrane serine 
protease 2 (TMPRSS2).27 TMPRSS2 expression is regulated 
by the androgen receptor in the prostate.28,29 Androgens 
have been hypothesised to also regulate TMPRSS2 expres-
sion in lung tissue, potentially explaining the increased 
mortality in male patients from COVID-19 seen consis-
tently across national health departments to varying 
degrees.30 Further analysis is needed of the observed 
association between male sex and 30-day all-cause 
mortality, which might be driven by biological differences 
between the sexes versus differences in high risk jobs, 
professional exposure, or other factors.31
Notably, we did not find any association between recent 
surgery and 30-day all-cause mortality, as previously 
described in a smaller case series.2 Given that delays in 
elective cancer surgeries might lead to deleterious 
outcomes, this finding should be taken into consideration 
if policies to delay treatments are being implemented, 
while acknowledging that many other factors exist that 
should be considered, such as surge capacity and provider 
availability.32,33 As the CCC19 cohort increases and matures, 
Figure 2: Primary and composite secondary outcome by cancer type, cancer status, and anticancer therapy
Mortality as a function of cancer type and status (A) and cancer type and therapy type (B). Composite outcome as a function of cancer type and status (C) and cancer 
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additional factors can be examined in greater detail, such as 
myelosuppression associated with cytotoxic chemotherapy, 
immune activation associated with immunotherapy, and 
risks specific to some cancer diagnoses and regimens.
Our study has some limitations, such that some 
observations should be interpreted with caution. Some 
notable regional variations in the primary and secondary 
outcomes exist. The Spanish subgroup had no ICU 
admissions and no patients put on mechanical venti-
lation, but had ten deaths. The Canadian subgroup had 
the highest proportion of patients admitted to hospital, 
yet had the numerically lowest rate of deaths of any of 
the regional subgroups. These findings, including the 
reduced risk of 30-day all-cause mortality associated 
with residence in Canada and the US-Midwest probably 
reflect regional differences in the response to COVID-19, 
and different timelines of the local pandemic, and 
deserve further study. Higher numbers of comorbidities 
were significantly associated with increased mortality; 
however, the number of events in the reference group 
was very low (three deaths). This variable also had a 
high inflation factor, indicating significant collinearity 
with other variables in the model. A cancer status of 
unknown was also associated with increased mortality, 
intermediate between the groups of present, stable, or 
responding, and present, progressive disease. These 
patients are likely to be a distinct subgroup—eg, having 
scans with mixed or equivocal findings or having 
recently started a new anticancer therapy without re-
assessment.
A strong association with 30-day all-cause mortality was 
observed in the subgroup treated with the combination of 
azithromycin plus hydroxychloroquine; this same effect 
was not seen in the subgroups treated with either drug 
alone. This combination was commonly used in patients 
who met the composite endpoint, possibly on the basis of 
the non-randomised study by Gautret and colleauges.34 
Therefore, hydroxychloroquine plus azithromycin might 
not be the cause of increased mortality, but instead were 
given to patients with more severe COVID-19. On the 
other hand, the US Food and Drug Administration have 
documented their concerns about the risk of prolonged 
QT inter vals when combining these medications.35 
Although our findings cannot be considered conclusive 
due to an inherent bias caused by the primarily 
retrospective nature of the study, these data still highlight 
the importance of establishing the aggregated risks and 
benefits of these medications in a prospective randomised 
trial setting before widespread application.36
This is primarily a retrospective cohort study designed 
for rapid patient accrual and data collection in an urgent 
global crisis. The lack of precise timing for events, as was 
required to meet IRB and General Data Protection 
Regulation requirements, introduces uncertainty into the 
exact timing of diagnostic, therapeutic, and outcome 
intervals. Although participating sites were strongly urged 
to comprehensively identify patients with concurrent 
cancer and COVID-19 diagnoses, selection bias is likely 
given that patients who are tested are generally symp-
tomatic, and thresholds for testing are lower in hospital 
settings. Community practices are somewhat under-
represented in this initial sample; therefore, this cohort 
might reflect more severe cases of COVID-19. We were 
unable to adjust for all the a priori potential prognostic 
variables in the multivariable models due to low numbers 
of events. Finally, we were not able to do an analysis 
comparing our cohort with patients with cancer without 
COVID-19 and patients without cancer with COVID-19. 
Such an analysis would better place the current data into a 
larger context.
In summary, this study of patients with cancer and 
COVID-19 reinforces several important considerations 
for clinical care, and emphasises the urgent need for 
more data. Longer-term follow-up and larger sample sizes 
are needed to more completely understand the effect of 
SARS-CoV-2 on outcomes in patients with cancer.
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